Studieoverzicht
BOOG nr.: |
Status: ( View all )
|
Indication: ( View all )
|
Subindication: |
Menopausal status: |
2021-02 ZEST | Active, not recruiting | Adjuvant | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2017-02 PERIDENO | Closed | Adjuvant | HER2-, any HR | Postmenopausal | ||||||||||||||
2014-03 OLYMPIA | Follow up | Adjuvant | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2014-02 BRAVO | Follow up | Advanced/metastatic | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2013-04 DIRECT | Follow up | Neoadjuvant | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2010-02 STOP&GO | Closed | Advanced/metastatic | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2010-01 NEO-ZOTAC | Closed | Neoadjuvant | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2006-06 ATX | Closed | Advanced/metastatic | HER2-, any HR | Both pre- and postmenopausal |